Skip to main content

Table 2 Efficacy parameters for prediction of clinical diagnosis 1 year post scan: modified H&Y stage ( n = 92)

From: Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCANTM) in subjects with clinically uncertain parkinsonian syndromes

Subjects with CUPS Clinical diagnosis at 1 year post-scan
Subgroup: modified H&Y stage <2 Subgroup: modified H&Y stage ≥2
PS Non-PS Total PS Non-PS Total
Abnormal ioflupane [ 123 I] images a 26 0 26 20 2 22
Normal ioflupane [ 123 I] images 2 20 22 1 21 22
Total 28 20 48 21 23 44
Statistic Result Exact 95% CI   Result Exact 95% CI P value/analysis method b
Sensitivity c 0.9286 (0.7650, 0.9912)   0.9524 (0.7618, 0.9988) 1.0000
Specificity d 1.0000 (0.8316, 1.0000)   0.9130 (0.7196, 0.9893) 0.4906
Accuracy 0.9583 (0.8575, 0.9949)   0.9318 (0.8134, 0.9857) 0.6673
Positive predictive value 1.0000 (0.8677, 1.0000)   0.9091 (0.7084, 0.9888) 0.2048
Negative predictive value 0.9091 (0.7084, 0.9888)   0.9545 (0.7716, 0.9988) 1.0000
  1. CI, confidence interval; CUPS, clinically uncertain parkinsonian syndrome; H&Y, Hoehn and Yahr; PS: parkinsonian syndrome. aAbnormal imaging types 1, 2 and 3. b P value is based on Fisher’s exact test. cSensitivity is equivalent to positive percent agreement. dSpecificity is equivalent to negative percent agreement.